Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boston Scientific’s Taxus stent proves efficacy in trial

Boston Scientific’s Taxus stent proves efficacy in trial

29th September 2010

Boston Scientific has published new clinical trial data which demonstrates the effectiveness of its Taxus Express stent among heart attack patients.

The medical technology firm has revealed results from the recent Horizons-AMI trial, which compared the safety and efficacy of the paclitaxel-eluting coronary stent system to bare-metal stenting in patients suffering an acute myocardial infarction.

It was found that users of the Taxus stent experienced significantly reduced rates of clinical and angiographic restenosis, as well as reductions in ischemia-driven target lesion revascularisation after a three-year follow-up period.

Dr Keith Dawkins, senior vice-president and chief medical officer for Boston Scientific's cardiology, rhythm and vascular group, said the data demonstrates the benefits the stent offers to a high-risk patient demographic.

He added: "Boston Scientific continues to support large clinical trials that provide the medical community data that can be used in combination with broader clinical judgment to develop optimal treatment strategies for challenging patient subsets."

Last week, the company announced that it is to acquire the asthma control device specialist Asthmatx in a deal valued at $193.5 million (122.6 million pounds).ADNFCR-8000103-ID-800089093-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.